On January 3, 2019 Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, reported that the Company will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 11:00 a.m. PST in San Francisco, CA (Press release, Verastem, JAN 3, 2019, View Source;p=irol-newsArticle&ID=2381972 [SID1234532403]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be available for 90 days.

On January 3, 2019 Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, reported that its 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (NSCLC) (KEYNOTE-495) (Press release, Personal Genome Diagnostics, JAN 3, 2019, View Source [SID1234532419]). This study will investigate the utility of biomarker-based triage for study participants with previously untreated advanced NSCLC. The PGDx elioTM tissue complete assay is being used during the enrollment process for the analysis of tumor mutational burden (TMB) status.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Study participants within groups defined by a biomarker-based classifier (gene expression profile [GEP] and TMB) will be randomized to receive pembrolizumab in combination with MK-4280 or lenvatinib. The study will involve more than 70 clinical sites worldwide.

"We are proud to collaborate with Merck on this trial. Merck is a leader in immune oncology and we view their selection of PGDx as a testament to our capabilities around TMB," said Doug Ward, Chief Executive Officer at PGDx. "With the kitted approach for the PGDx elio portfolio, we aim to expand patient access to comprehensive, local genomic testing and reduce turn-around time for results that inform critical treatment decisions for patients worldwide."

PGDx provides genomic solutions from biomarker discovery to companion diagnostic development through its CAP/CLIA certified laboratory and is developing a portfolio of regulated tissue-based and liquid biopsy genomic products to enable local next-generation sequencing (NGS) testing in laboratories worldwide.

On January 3, 2019 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, reported that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will present at the 37TH Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 at 4:00 pm PT in San Francisco (Press release, Ultragenyx Pharmaceutical, JAN 3, 2019, View Source [SID1234532435]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live and archived webcast of the company presentations will be accessible from the company’s website at View Source The replay of the webcast will be available for 90 days.

On January 3, 2019 Aduro Biotech, Inc. (NASDAQ: ADRO) reported that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the 37TH Annual J.P. Morgan Healthcare Conference in San Francisco, California on Thursday, January 10, 2019 at 11:30 am PST (Press release, Aduro Biotech, JAN 3, 2019, View Source;p=RssLanding&cat=news&id=2381999 [SID1234532455]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live webcast and subsequent archived recording of this and other company presentations, please visit the investor section of Aduro’s website at www.aduro.com. The archived webcast will remain available for replay on Aduro’s website for 30 days.

On January 3, 2019 Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, reported that it is scheduled to present at the Biotech Showcase(TM) 2019 at the Hilton San Francisco Union Square in January 2019 (Press release, Kiadis, JAN 3, 2019, View Source [SID1234533320]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Biotech Showcase 2019
January 7-9, 2019
Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA
Hilton/Yosemite A, Ballroom Level
Arthur Lahr, CEO, will present on Monday, January 7 at 3:30pm PST.

The Kiadis management team will also host one-on-one meetings from January 7-10 in San Francisco